FDA panel OKs new class of HIV drug

Roehr, Bob
April 2007
Bay Area Reporter;4/26/2007, Vol. 37 Issue 17, p17
The article reports that a committee of the U.S. Food and Drug Administration has recommended approval of Pfizer Inc.'s CCR5 inhibitor maraviroc, trademarked Celsentri. Maraviroc belongs to a class of anti-HIV drugs developed for heavily treatment-experienced patients. It works against the R5 coreceptor and is effective only against HIV patients with virus that uses the R5 coreceptor.


Related Articles

  • US Okays More Potent HIV Drug Formulation.  // Clinical Infectious Diseases;2/15/2005, Vol. 40 Issue 4, preceding p1 

    This article reports that the U.S. Food and Drug Administration has granted approval to a more potent formulation of Roche AG's HIV drug invirase, meaning that patients will not need to take as many of the pills.

  • Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals. Bichoupan, Kian; Dieterich, Douglas // Drugs;Jun2014, Vol. 74 Issue 9, p951 

    Approximately 30 % of HIV-infected patients are co-infected with hepatitis C virus (HCV). After the release of highly active antiretroviral therapy, liver disease has become the leading cause of morbidity and mortality in HIV patients. Prior to 2011, HCV treatment with pegylated-interferon and...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Feb2011, Vol. 25 Issue 2, p123 

    No abstract available.

  • Enfuvirtide. Coleman, Craig I.; Musial, Bogdan L.; Ross, Jack // Formulary;Apr2003, Vol. 38 Issue 4, p204 

    Focuses on enfuvirtide, the first member of antiretrovirals to gain U.S. Food and Drug approval for the treatment of HIV-1 infection. Pharmacology; Pharmacokinetics; Clinical trials of enfuvirtide; Safety and tolerability; Drug interactions; Dosage and administration; Cost. INSET: Formulary...

  • New class of anti-HIV drug approved.  // European Pharmaceutical Executive;Jun2007, p9 

    The article reports on the recommendation of the U.S. Food and Drug's (FDA) Antiviral Drugs Advisory Committee on the approval of Pfizer Inc.'s maraviroc, a chemokine receptor (CCR5) antagonist. It is designed to treat patients infected with CCR5-tropic human immunodeficiency virus-1 (HIV),...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Nov2008, Vol. 22 Issue 11, p917 

    The article offers news briefs related to developments related to antiviral agents. Pfizer Inc. has released data from a study of HIV patients, in which findings point to the need for proper patient selection prior to treatment with CCR5 therapies. The U.S. Food and Drug Administration (FDA)...

  • Generic abacavir sulfate tablets approved.  // AIDS Alert;Aug2010, Vol. 25 Issue 8, p96 

    The article reports on the tentative approval of a generic formulation of abacavir sulfate tablets by the U.S. Food and Drug Administration (FDA).

  • Trends in the prescription drug plans delivering the Medicare Part D Prescription Drug Benefit. Brill, Joel V. // American Journal of Health-System Pharmacy;8/1/2007 Supplement, Vol. 64, pS3 

    Purpose. The potential impact of the Democrat-proposed Medicare drug program reform plan; possible Congressional actions in 2007; the standard Medicare prescription drug benefit; the use of low-income subsidies (LIS); and trends in 2006 and 2007 Medicare prescription drug plan (PDP) offerings,...

  • FDA approves maraviroc. Roehr, Bob // Bay Area Reporter;8/9/2007, Vol. 37 Issue 32, p17 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved Pfizer's Maraviroc, the first anti-HIV drug that targets the CCR5 coreceptor on the outside of the cell. The drug, under the trade name Selzentry, has been approved for use in treatment experienced patients. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics